Boston Scientific Corporation (NYSE: BSX) has announced it has entered into a definitive agreement to acquire Relievant MedSystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of US$850 million and undisclosed additional contingent payments based on sales performance over the next three years.
Latham & Watkins LLP represented Relievant MedSystems in the transaction with a corporate deal team led by New York/Orange County partner Charles Ruck and Bay Area partners Saad Khanani and Kathleen Wells, with associates Donna Kim, Kristine LaVeau, Rebecca Dixon, and Justin Tzeng. Advice was also provided on data privacy matters by Bay Area partner Heather Deixler; on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with associates Robert Yeh and Aldrich Huang; on regulatory matters by Bay Area partner Joshua Holian and Washington, D.C. counsel Patrick English, with associates Alisha Nguyen and Emani Walks; on healthcare regulatory matters by Washington, D.C. partner Ben Haas and Bay Area partner Betty Pang, with associate Seth Olson; on anti-corruption matters by Washington, D.C. partner Erin Brown Jones and counsel Andrew Galdes, with associate C.J. Rydberg; on tax matters by Bay Area partner Kirt Switzer, with associate Jake Meninga; and on executive compensation and employee benefits matters by Bay Area partner Ashley Wagner, with associate Nimra Syed.